Phargentis

Executive Summary

Phargentis SA is a privately held, virtual drug development company headquartered in Lausanne, Switzerland. Founded in 2015, the company specializes in creating complex dosage forms for generic drugs and innovative 'SuperGeneric' products. By focusing on formulations that are difficult to replicate, Phargentis enables early market entry for generic alternatives, thereby capturing value before standard generics commoditize the market. The company operates on a virtual model, outsourcing R&D and manufacturing, which allows it to maintain low overhead while leveraging specialized expertise. Phargentis licenses its developed products to leading pharmaceutical partners who handle global commercialization. This asset-light strategy reduces capital risk and accelerates time-to-revenue. The company's pipeline targets high-value, off-patent drugs with significant barriers to entry, such as modified-release formulations, injectables, and combination products.

Upcoming Catalysts (preview)

• 2026First product licensing deal with a major pharmaceutical partner70% success
• Q3 2026Completion of pivotal bioequivalence study for a lead generic candidate65% success
• 2027Expansion of pipeline into new therapeutic areas or dosage forms50% success